FDA product code · General Hospital · Class 2
DXT: Injector And Syringe, Angiographic
DXT is FDA's product code for "Injector And Syringe, Angiographic": a Class 2 device classified under 21 CFR 870.1650, reviewed by the General Hospital panel.
510(k) review time for DXT
Across 29 510(k) clearances under DXT decided from 2018-01-01 to 2026-10-06, the median was 154 days from FDA receipt to decision. Half took between 87 and 264 days, and 80% were decided within 265 days. These are past clearances, not a forecast for a new submission.
| Fastest | 27 |
|---|---|
| 25th percentile | 87 |
| Median | 154 |
| 75th percentile | 264 |
| 80th percentile | 265 |
| 90th percentile | 275 |
| Slowest | 462 |
| Year | Median days | n |
|---|---|---|
| 2018 | 93 | 9 |
| 2026 (to 10-06, partial) | 265 | 6 |
Source: openFDA 510(k) records, snapshot of 2026-10-06 (openFDA data as of 2026-09-28). Compare 510(k) review times across all device types, see every code side by side in the Clearance Timeline Estimator, or browse the clearances themselves in PredicateScope.
DXT in the public FDA record
| 510(k) clearances, all years | 210 |
|---|---|
| Device recalls | 70 |
| Establishment listings | 397 |
| GUDID device identifiers | 1,743 |
Counts of records, not of devices or events. Adverse event reports for DXT are in MAUDEScope, as counts with the query shown: MAUDE has no denominator, so a report count is not a rate and does not show that a device caused an event.
FDA-recognized standards that cite DXT
No FDA recognized consensus standard cites DXT by product code. Horizontal standards such as biocompatibility, sterilization and software standards can still apply.
Source: FDA Recognized Consensus Standards, snapshot of 2026-09-01. Search them all in the Consensus Standards Lookup.